D
uring the first few weeks of life when illness and the resultant laboratory testing are most intense, preterm very-low-birthweight (VLBW) newborn infants weighing not more than 1.5 kg at birth commonly receive allogeneic RBC transfusions. To ensure optimal efficacy and avoid decreased survival of transfused RBCs and to thereby limit the number of RBC transfusions, it is important that allogeneic RBC units stored in the blood bank must be high quality. When RBCs stored for 42 days in extended storage media (e.g., AS-1, AS-3, AS-5, and AS-7) are transfused to adults, an average of 85% of the transfused RBCs remain in the recipient's circulation after 24 hours. 1 In the only prior study of 24-hour RBC posttransfusion recovery (PTR 24 Cr has been used exclusively for FDA licensing, radiation exposure of infants, children, and pregnant women is deemed ethically unacceptable in the United States. 3 In Europe, similar concerns about radiation exposure have been extended to adults. Consequently, the European standards for licensing approvals of RBC transfusion commercial devices do not include a requirement for PTR 24 determination. 4, 5 No prior RBC kinetic studies have performed direct statistical comparisons of PTR 24 in infants and adults. This study offers this comparison by utilizing PTR 24 data from three previously reported neonatal RBC kinetic studies 2, 6, 7 and from four adult RBC studies. [8] [9] [10] [11] Doing so is desirable for comparing PTR 24 results in two such markedly different subject populations with their different RBC circulatory environments. 12 The different circulatory environments have been demonstrated in studies reporting markedly different long-term RBC survival in newborns and in adults. Specifically, adult RBCs survive approximately half as long in the circulation of infants as in adults. 7 The opposite has also been demonstrated: fetal
RBCs from infants delivering at term survive approximately twice as long when in the adult circulation as they do in newborn infants. 13, 14 Labeling of RBC surface proteins with biotin (vitamin B7), followed by flow cytometric enumeration of the biotinylated RBCs (BioRBCs) remaining in circulation, offers an alternative method that avoids exposure of transfused subjects to radioactivity. 15 Employing the biotin method also adds two additional important capabilities compared to 51 Cr method: 1) the ability to label RBCs at multiple, discrete biotin densities (e.g., to compare effects of storage media on RBC survival); this approach allows for simultaneous quantification of RBC volume and survival in the same subject; and 2) the ability to accurately tracking BioRBC survival for at least 95% of the RBC life span. The latter is not possible with 51 Cr-labeled RBCs because of elution of the chromium that varies unpredictably between individuals from 0.5% to 2.5% per day, thus limiting quantification of RBC survival to 28 days. 16 Although most adult studies were performed with 51 Cr and the sole neonatal study was done with BioRBCs, we infer that the reported difference between PTR 24 for adults and neonates is not likely attributable to differences in the labeling methods because the two methods yield similar results when employed simultaneously. In healthy adults in which 51 Cr-and biotin-labeled autologous RBCs were concurrently administered, no differences in PTR 24 
MATERIALS AND METHODS
The studies received institutional review board approval from both study sites, the University of Iowa and the University of Cincinnati. Written informed consent was required and obtained from all adult study subjects and from the parents of study infants.
Study subjects
Neonatal subjects included a convenience sample of 46 anemic infants with an estimated gestational age at birth of not more than 31 weeks who were being ventilated for respiratory distress and anticipated to survive. All neonates were anemic and receiving clinically indicated allogeneic adult donor RBC transfusions as reported previously. 2, 6, 7 Infants with major congenital anomalies were excluded.
Adults included healthy individuals meeting criteria as blood donors. All had been enrolled in previously reported RBC kinetic research studies in which autologous RBCs labeled with 51 Cr were reinfused. [8] [9] [10] [11] Neonatal and adult study protocols Neonatal subjects received allogeneic BioRBCs that had been leukoreduced (Leukotrap RC system, Medsep) and stored up to the 42-day FDA limit while maintained in the blood bank per hospital protocol in AS-3 RBC storage media (Nutricel, Medsep Corporation, formerly Cutter Biologicals) before biotin labeling as described below. Actual storage time depended on blood compatibility and availability and varied from 2 to 42 days. On the day that a clinical transfusion was ordered, aliquots were taken from blood bank RBC units preassigned to each infant, irradiated (3000 cGy) on the same day as the RBC transfusion, and administered according to standard transfusion practice for neonates at our institution, that is, as 15 mL/kg RBCs at hematocrit (Hct) levels of 85 6 2%. The first 11 to 14 mL/kg of donor RBCs was transfused as a routine clinical transfusion over 3 to 4 hours; the remaining 1 to 4 mL/ kg was labeled with biotin at one to four separate BioRBC densities and then mixed and transfused in under 15 minutes through an 18-mm filter to remove microaggregates (Hemo-Nate, Utah Medical Products) immediately after the conclusion of the clinical transfusion.
Adult study subjects donated 500 mL of blood, which was stored in AS-3 or AS-5 RBC storage medium (Optisol, Terumo BCT, Inc.) after undergoing in-line leukoreduction filtration (Terumo BCT, Inc.). These autologous RBC units were stored in the blood bank for 0, 21, 35, or 42 days before readministration; approximately 10 mL of RBCs was labeled with 51 Cr and reinfused at a rate of 5 to 7 mL/min.
Laboratory methods

Biotin labeling of neonatal RBCs administered to neonates
Adult donor allogeneic RBCs administered to neonates were biotinylated as previously described. 18 Briefly, RBCs
were washed using a carbonate-buffered dextrose sodium phosphate wash solution to remove plasma and resuspended at a Hct of 25%. Hct adjustment was verified using an automated hematology system (Sysmex XE-2100, Sysmex). Subsequently, RBCs were biotinylated using the biotin 3-sulfo-N-hydroxysuccinimide ester (EZ-LINK sulfo-NHS-biotin, Pierce Chemical). Depending on the primary objectives of the original study, up to four separate concentrations ranging from 6 to 162 mg of sNHS-biotin/mL packed RBCs were chosen. These choices produce discreet biotin labeling densities that can be individually tracked for at least 95% of the RBC lifetime. Minutes before transfusion, a 0.5-mL sample of the BioRBC mixture was taken for bacterial culture.
BioRBC flow cytometric determination
After infusion, the number of BioRBCs for each of the different BioRBC populations was determined by flow cytometry and expressed as a fraction of the total number of RBCs counted. Flow cytometric measurements were performed in triplicate on 10 mL of leftover whole blood salvaged from laboratory blood testing as described previously. 18 For each sample, 1 3 10 6 RBCs were counted. 19 For the rare samples exhibiting overlap in the fluorescence histogram between the BioRBC peaks or between the unlabeled RBCs and the lowest biotin density, mixed modeling was used to calculate the proportion of RBCs in each population as previously described. 20 The lower limit of quantitation for individual BioRBC density peaks is 0.06% of total RBCs. 21 For BioRBCs, PTR 24 was calculated as the ratio of the proportion of each population of BioRBCs remaining in the circulation at approximately 24 hours (15-36 hr per study protocol) after infusion of the BioRBCs relative to the proportion of the same population of BioRBCs in circulation at the first available time point (usually 10 to 180 min after BioRBC transfusion, but occasionally as late as to 180 min posttransfusion per study protocol).
Cr labeling of adult RBCs
On the day of reinfusion, each study RBC unit was inspected for signs of hemolysis, clotting, and discoloration, and the bacterial culture taken from each unit 5 days before was confirmed to be negative. The unit was then mixed by hand and an aliquot of the RBCs was collected from the unit and labeled with 370 to 740 kBq of 51 Cr using standard techniques over approximately 90 minutes as follows. 22 The labeling agent, sodium chro- Cr-labeled RBCs was drawn up into a syringe and infused.
Determination of radioactivity in blood containing 51 Cr-labeled RBCs
The amount of RBCs and total radioactivity infused were determined using the method of Moroff and coworkers 22 as recommended by the International Committee for Standardization in Hematology. 16 The infusion of the radiolabeled aliquot and all subsequent blood sampling was carried out according to study site standard operating procedures and as described by Moroff and coworkers. Cr-specific activity after correcting for radioactive decay and for the loss of 51 Cr label over time using an elution multiplicative factor. 23 PTR 24 was calculated as the ratio of the radioactivity per milliliter of whole blood in the 24-hour sample to the radioactivity per milliliter of whole blood extrapolated to Time 0 from the first seven samples. All
51
Cr samples were counted at the same time.
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Cr-labeled RBCs, Time 0 was determined by calculating the 51 Cr counts (adjusted for Hct) for time points 5, 7.5, 10, 12.5, 15, and 20 minutes and extrapolated using the natural logarithm of the regression line of these values to Time 0. The PTR 24 was determined by dividing the 24-hour time point counts by the Time 0 counts. 23 
Statistical analysis
Linear mixed-model analysis was used to examine the relationship between PTR 24 and RBC storage time in newborns and in adults. This method of analysis properly accounts for subjects who had more than one data point. From this analysis, estimates of the slopes were obtained for newborns and for adults. The null hypothesis was that there was no effect of storage time on PTR 24 (H o , slope 5 0). For each group, we also tested for a difference in slope between the groups. To assess for potential effects of neonatal demographic factors (i.e., sex, birthweight, gestational age, weight at study, and age at study) on the relationship between PTR 24 and RBC storage time linear mixed-model analysis was performed on the newborn data. To assess potential effects of sex and age, similar analysis was performed on the adult data. All statistical analyses were performed using computer software (SAS, Version 9.4, SAS Institute). A p value of not more than 0.05 was considered significant.
RESULTS
Demographics
For the 46 neonates mean 6 SD birthweight and gestational age were 907 6 254 g and 27.1 6 1.8 weeks, respectively. There were 21 (46%) males and eight (17%) twins; the rest were singletons. Four of the 46 (8%) were small for gestational age (<2 SD for weight adjusted for sex, multiple birth, and gestational age at birth). 24 As per inclusion criteria, all received mechanical ventilation within the first day of life. Mean postnatal age at the time of the BioRBC transfusion was 16 6 16 days (range, 0-57 days). The mean 6 SD blood bank storage time of the RBC transfused to the neonates was 12 6 9 days (range, 2-42 days). The mean 6 SD posttransfusion times of the blood sampling used in calculating PTR 24 
Comparison of neonatal and adult PTR 24 relative to the duration of storage
The developmental difference in storage effect on PTR 24 was compared between infants and adults by characterizing the dependence on storage duration for each group. For the infant data, we initially performed linear mixedmodel analysis to evaluate the possibility that there might be an effect of BioRBC density on the relationship between PTR 24 and RBC storage duration. No such effect was detected as judged by finding no difference in slopes among the three tiers of densities (p 5 0.42); accordingly, our final slope comparison pooled the data from the three BioRBC tiers of densities. There was a significant difference in the Time 0 y-axis intercepts of the three BioRBC density tiers: mean (95% CI), high 99.7% (96.5%-102.9%), medium 101.4% (98.4%-104.3%), and low 102.1% (99.2%-105.0%). Because these all were not significantly different from 100%, we infer that these differences are of no physiologic relevance.
The finding of no difference in slopes mandated adoption of a model that had a common slope but significantly different intercepts among the three tiers of densities (p < 0.001). For all subsequent analyses, the model with a common slope but different intercepts for the three BioRBC densities was used. Applying this linear mixed model to the combined newborn and adult data indicated that there was no significant decline in PTR 24 with increasing storage duration in newborns (slope, 0.13%/day [95% CI, 20.32 to 0.06]; p 5 0.18). In contrast, the From this fitted mixed model based on the combined newborn and adult data, an estimate of the mean PTR 24 at 42 days of RBC storage (the maximum duration allowed for AS-3 and AS-5 by the FDA) was then computed for allogeneic RBCs administered to adult study subjects and to a single, combined group of newborns. For adults, mean PTR 24 at 42 days of RBC storage was 83.8% (95% CI, 81.9%-85.7%). This is consistent with previous reports. 1 In contrast, for the combined newborn group the estimated mean PTR 24 at 42 days of RBC storage of 95.9% (95% CI, 90.1%-101.8%) was significantly higher (p 5 0.0002).
We investigated the generalizability of these observations to other infants by examining the effects of demographic factors. None of the infant variables (sex p 5 0.55; gestational age at birth p 5 0.82; birthweight p 5 0.84; weight at study p 5 0.99; and postnatal age at study p 5 0.56) had a significant effect on the slope of PTR 24 versus duration of storage by linear mixed modeling. Likewise, there was also no significant effect of sex (p 5 0.85) or age (p 5 0.33) on the slope of PTR 24 in adults.
DISCUSSION
The present data using extended RBC storage media demonstrate striking differences in the 24-hour recovery of transfused RBCs in newborns compared to adults . Unlike PTR 24 of allogeneic RBCs transfused to adults, allogeneic RBCs transfused to newborn infants showed no decrease in PTR 24 with increasing duration of RBC storage. Moreover, when the newborn and adult slopes for the plots of PTR 24 versus duration of RBC storage were compared, the two differed significantly. Because decreased survival of transfused RBCs lessens the effect of the transfusion on correcting anemia and thus increases the need for subsequent RBC transfusions, RBC survival is import.
Ethical considerations dictated two additional factors that differed between the neonatal and adult data sets: 1) biotin was the label for newborns and 24 values compared to allogeneic RBCs. Thus, the source difference would have masked a neonatal-adult difference, not produced one making source difference an explanation for the differences observed. We therefore contend there is no sound basis for concluding that these two methodologic differences negate the main findings of this study.
The precise mechanisms responsible for the differences observed in the newborn and adult PTR 24 results are currently unknown. However, previous observations suggest a likely role for the immune system because of the comparative immaturity of the VLBW infants' immune system versus adults. Indeed, substantial attenuation of acquired immunity in newborn infants has long been recognized. 25 This developmental difference is the primary basis for the AABB recommendation that infants receiving RBC transfusions require pretransfusion antibody screening only once in the first 4 months of life, providing that the initial result is negative. 26 The comparative function of the innate immune system (i.e., tissue macrophages and related cells such as Kupffer cells), likewise, must be considered, as these cells are responsible for the rapid and efficient removal of senescent RBCs and RBCs that have sustained posttransfusion "storage lesions." 27 In the present report, macrophages of newborns seem to have diminished ability to remove RBCs sustaining ex vivo storage lesion injury. Future studies defining how macrophages from infants and adults respond to different "eatme signals" in their central role in controlling apoptotic programmed cell death will be important. Thus, based on the present findings, we speculate that neonatal macrophages respond differently to these RBCs with storage lesions than adult macrophages, thus reflecting their immaturity. Key recognition, engulfment, and degradation molecules associated with normal functioning of adult macrophages include CD47, CD200, phosphatidylserine, thrombospondin-1, and likely other factors. These capacities may be ineffective-or missing-in newborn infant macrophages as a result of their developmental immaturity. 28, 29 Notable limitations in the present study include small number of infant PTR 24 measurements for RBCs stored longer than 3 weeks. Moreover, the sample sizes for both newborns (n 5 46) and adults (n 5 76) are relatively modest. Although PTR 24 data for 11 of the newborn infants included in this study have been reported previously, 2 this study expands these data by more than threefold. We also acknowledge that in this analysis of PTR 24 among groups of study subjects derived from several previously published studies, institution-specific factors beyond our control may have affected our findings and thus be considered a limitation. Specifically, due to maldistribution of neonates and adults at the two study sites, it was not possible to perform a subanalysis of adults versus VLBW neonates within a single institution. A final study limitation is that the adult allogeneic RBCs administered to neonates were irradiated while the adult autologous RBCs administered to adults were not. This seems unlikely to be an important limitation since in adults, PTR 24 of RBCs irradiated 2 days before transfusion demonstrated no significant decline in PTR 24 while a 14-day interval demonstrated a significant decline. 30 In summary, observations presented here provide evidence of a significant effect of storage duration on PTR 24 in adults, but not newborn infants. These observations support the practice to transfuse RBCs, stored throughout the currently permitted FDA 42-day storage limit for RBCs, to infants receiving small-volume transfusions during the anemia of prematurity-rather than limiting storage to fewer days. Also, given the moratorium on radiation exposure to children in research, the biotin label seems to be the best alternative to radioactive 51 Cr for RBC kinetic studies in children. 15 
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